Bullish indicating open at $55-$60, IPO prices at $37
Alan Ezekowitz, a director at Septerna, Inc. (NASDAQ:SEPN), has recently increased his stake in the company through a series of stock purchases. According to a recent SEC filing, Ezekowitz acquired a total of 86,681 shares of Septerna common stock over three days, with transactions occurring on March 4, 5, and 6, 2025. The purchases come as the stock has declined over 70% in the past six months, according to InvestingPro data.
The purchases were made at varying prices, reflecting a weighted average price per share. On March 4, Ezekowitz bought 7,491 shares at prices ranging from $6.40 to $6.44. The following day, he acquired 37,835 shares, with prices between $5.68 and $6.12. Finally, on March 6, he purchased an additional 41,355 shares, with prices falling between $5.82 and $6.23. While the company maintains a strong current ratio of 10.08, indicating solid short-term liquidity, InvestingPro analysis shows the company is quickly burning through cash.
In total, these transactions amounted to approximately $515,934, with the price per share ranging from $5.8216 to $6.3468. Following these acquisitions, Ezekowitz’s total holdings in Septerna have increased to 104,101 shares. With a market capitalization of $263.31 million and trading significantly below its 52-week high of $28.99, InvestingPro analysis suggests the stock is currently overvalued despite its recent decline. Subscribers can access 12 additional ProTips and comprehensive financial metrics for deeper analysis.
In other recent news, Septerna Inc . announced the discontinuation of its Phase 1 clinical trial for SEP-786 due to elevated bilirubin levels in participants, despite no serious adverse events being reported. The company plans to shift its focus to alternative compounds in its pipeline, including SEP-631, which is expected to enter clinical trials for mast cell diseases later this year. Financially, Septerna reported $137.5 million in cash and marketable securities as of September 30, 2024, bolstered by $302.6 million from its IPO, which is expected to fund operations into the second half of 2027. In light of these developments, JPMorgan maintained its Overweight rating with a $38 price target for Septerna, while Cantor Fitzgerald also reaffirmed an Overweight rating with a $50 target, citing the company’s growth potential in the hypoPTH market. Additionally, Septerna appointed Gil Labrucherie as its new Chief Financial Officer, bringing extensive experience in finance and business development to strengthen the company’s financial strategy. Despite the trial halt, Septerna remains committed to advancing its pipeline and exploring new PTH1R agonists for hypoparathyroidism. The company’s strategic focus on innovation and its robust financial position continue to garner analyst support.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.